Alto Neuroscience, Inc. today announced a favorable outcome from the planned interim analysis for its Phase 2b trial of ALTO-300. This trial is evaluating ALTO-300 as an adjunctive treatment for patients with major depressive disorder (MDD).
Based on the results of this interim analysis, the Phase 2b trial will continue as planned. The analysis recommended an increase in the biomarker-positive sample size, a strategic adjustment designed to improve the overall probability of success for the trial.
Topline results from the complete study sample for the ALTO-300 Phase 2b trial are now expected in mid-2026. This positive interim outcome provides further validation for Alto's precision psychiatry approach in developing targeted treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.